Market Place
Sourcing Support
Daiichi Sankyo Light on Inequalities and Unmet Needs With Cardio Disease
01 Sep 2024 //
BUSINESSWIRE
New Japanese Patent For Edoxaban
20 Feb 2024 //
PRESS RELEASE
The dossier of Edoxaban is available for B2B partners!
13 Sep 2023 //
PRESS RELEASE
Four-year follow-up data reinforces the safety of treatment with edoxaban
25 Aug 2023 //
BUSINESSWIRE
USDMF for Edoxaban API has been submitted Based On Our Process Expertise
27 Mar 2023 //
PRESS RELEASE
Zydus`s Generic Edoxaban Receives Approval in the U.S.
16 Nov 2022 //
FDA
Data strengthens important role of LIXIANA in patient with atrial fibrillation
28 Aug 2022 //
BUSINESSWIRE
Edoxaban Noninferior to Warfarin in Atrial Fibrillation After TAVI
01 Sep 2021 //
ESCARDIO
New data support the use of LIXIANA ® in patients with atrial fibrillation (AF)
28 Aug 2021 //
BUSINESSWIRE
New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA®
26 Apr 2021 //
BUSINESSWIRE
Daiichi submits application in Japan for expanded usage for anticoagulant
11 Sep 2020 //
PHARMABIZ
Results of 12-month analysis data from ETNA-AF non-interventional study out
31 Aug 2020 //
PRNEWSWIRE
Daiichi Sankyo phase 3 study of anticoagulant, edoxaban meets primary endpoint
31 Aug 2020 //
PHARMABIZ
New 12-month analysis data from ETNA-AF non-interventional study
30 Aug 2020 //
PRNEWSWIRE
ETNA-AF-Europe Registry Data on LIXIANA®?(edoxaban) Published
19 Aug 2020 //
PRNEWSWIRE
Rates of Bleeding and Venous (VTE) Events Reported After 12 Months of Edoxaban
14 Jul 2020 //
PRNEWSWIRE
European Results From Global ETNA-AF Registry Show Low Bleeding
14 Oct 2019 //
PR NEWSWIRE
Daiichi Sankyo announces positive results for Lixiana combination
03 Sep 2019 //
CLINICALTRIALSARENA
Daiichi Sankyo Presents +ve Results of the ENTRUST-AF PCI Study of edoxaban
03 Sep 2019 //
PR NEWSWIR
Daiichi-Sankyo, Bayer, Otsuka & Others Called Out for UK Advertisement Breaches
12 Aug 2019 //
RAPS
List of New Paragraph IV Certifications as of March 13, 2019
18 Mar 2019 //
FDA
AMAG Pharma to buy US-based biopharma company, Perosphere Pharmaceuticals
14 Dec 2018 //
PHARMABIZ
Daiichi Sankyo Presents Analyses from Global ETNA-AF Programme of Oral edoxaban
31 Aug 2018 //
PR NEWSWIRE
Daiichi Sankyo & Menarini Enter Licensing Agreement for Commercializing LIXIANA®
29 Jun 2018 //
BUSINESSWIRE
Following FDA win, Portola loses CEO William Lis
04 Jun 2018 //
ENDPTS
Portola`s Andexxa bleeding antidote wins FDA nod
08 May 2018 //
FIERCE PHARMA
Daiichi Sankyo takes another big whack at U.S. sales operations
06 Mar 2018 //
FIERCE PHARMA
Daiichi Sankyo begins phase 3 ENVISAGE-TAVI AF study of once-daily Lixiana
08 May 2017 //
PHARMABIZ
Daiichi Sankyo Europe GmbH Roteas (edoxaban) Receives Approval In Europe
05 May 2017 //
EMA
Daiichi Sankyo begins clinical registry of venous thromboembolism
14 Mar 2017 //
PHARMABIZ
Daiichi Sankyo, Inc. Announces New Analyses of Once-Daily SAVAYSA® (edoxaban)
13 Mar 2017 //
PR NEWSWIRE
Six new medicines endorsed for EU approval
27 Feb 2017 //
PHARMATIMES
Daiichi Sankyo phase 3b ENSURE-AF study of once-daily Lixiana in patients
30 Aug 2016 //
PHARMABIZ
Servier Canada to market Daiichi Sankyo`s anti-coagulant edoxaban in Canada
27 Jun 2016 //
PHARMABIZ
Daiichi caps layoffs drive by melding NJ ops into one smaller HQ
25 Apr 2016 //
FIERCE PHARMA
Hoping to jump-start Lixiana, Daiichi Sankyo taps Merck for EU market assault
22 Feb 2016 //
FIERCE PHARMA MARKETING
Daiichi Sankyo inks marketing pact with Daewoong Pharmaceutical
29 Dec 2015 //
BIOSPECTRUM ASIA
Four therapies approved for use on NHS Scotland
10 Nov 2015 //
PHARMATIMES
NICE recommends blood-thinning drug edoxaban
23 Sep 2015 //
EUROPEAN PHARMACEUTICAL REVIEW
NICE recommends edoxaban for deep vein thrombosis
26 Aug 2015 //
EUROPEAN PHARMACEUTICAL REVIEW
Daiichi clot-buster wins a NICE green light, but still faces an uphill track
12 Aug 2015 //
FIERCE PHARMA
UK launch for Daiichi`s bloodthinner Lixiana
09 Jul 2015 //
PHARMATIMES
Daiichi`s Lixiana (Edoxaban) Approved in EU For Stroke
05 Jul 2015 //
EMA
Daiichi`s LIXIANA® (Edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular AF, DVT and PE
27 Jun 2015 //
DAIICHI SANKYO
BMS` Opdivo backed as melanoma therapy in EU
27 Apr 2015 //
PM LIVE
Eleven Medicines Leap Closer To Approval In Europe
26 Apr 2015 //
PHARMATIMES
